US 12,473,373 B2
Bispecific antibody molecules binding to CD3 and EGFRvIII
Anne Freimoser-Grundschober, Schlieren (CH); Thomas Hofer, Schlieren (CH); Ralf Hosse, Schlieren (CH); Ekkehard Moessner, Schlieren (CH); Valeria G. Nicolini, Schlieren (CH); Pablo Umaña, Schlieren (CH); Inja Waldhauer, Schlieren (CH); Wolfgang Richter, Basel (CH); Alexander Knaupp, Penzberg (DE); and Halina Trochanowska, Schlieren (CH)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Sep. 8, 2023, as Appl. No. 18/244,135.
Application 18/244,135 is a division of application No. 18/307,400, filed on Apr. 26, 2023.
Application 18/307,400 is a division of application No. 16/721,254, filed on Dec. 19, 2019, granted, now 11,672,858, issued on Jun. 13, 2023.
Claims priority of application No. 18214994 (EP), filed on Dec. 21, 2018.
Prior Publication US 2024/0042022 A1, Feb. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/3053 (2013.01) [A61K 39/39558 (2013.01); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C07K 16/2863 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01)] 30 Claims
 
1. A bispecific antibody molecule that binds to EGFRvIII and CD3 comprising:
(a) a first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain comprises: a VH comprising a HCDR 1 comprising the amino acid sequence SYAMN (SEQ ID NO: 2), a HCDR 2 comprising the amino acid sequence RIRSKYNNYATYYADSVKG (SEQ ID NO: 3), and a HCDR 3 comprising the amino acid sequence HTTFPSSYVSYYGY (SEQ ID NO: 5), and a VL comprising a LCDR 1 comprising the amino acid sequence GSSTGAVTTSNYAN (SEQ ID NO: 8), a LCDR 2 comprising the amino acid sequence GTNKRAP (SEQ ID NO: 9), and a LCDR 3 comprising the amino acid sequence ALWYSNLWV (SEQ ID NO: 10);
(b) a second antigen-binding domain that binds to EGFRvIII, wherein the second antigen-binding domain comprises: a VH comprising a HCDR 1 comprising the amino acid sequence SYWIA (SEQ ID NO: 85, a HCDR 2 comprising the amino acid sequence VIHPYDSDTRYSPSFQG (SEQ ID NO: 86), and a HCDR 3 comprising the amino acid sequence VSRSSYAFDY (SEQ ID NO: 87), and a VL comprising a LCDR 1 comprising the amino acid sequence KSSQSVLYSSNNKNYLA (SEQ ID NO: 89), a LCDR 2 comprising the amino acid sequence WASTRES (SEQ ID NO: 90), and a LCDR 3 comprising the amino acid sequence QQQRDGPPVT (SEQ ID NO: 91);
(c) a third antigen-binding domain that binds to EGFRvIII, wherein the third antigen-binding domain comprises: a VH comprising a HCDR 1 comprising the amino acid sequence SYWIA (SEQ ID NO: 85), a HCDR 2 comprising the amino acid sequence VIHPYDSDTRYSPSFQG (SEQ ID NO: 86), and a HCDR 3 comprising the amino acid sequence VSRSSYAFDY (SEQ ID NO: 87), and a VL comprising a LCDR 1 comprising the amino acid sequence KSSQSVLYSSNNKNYLA (SEQ ID NO: 89), a LCDR 2 comprising the amino acid sequence WASTRES (SEQ ID NO: 90), and a LCDR 3 comprising the amino acid sequence QQQRDGPPVT (SEQ ID NO: 91); and
(d) an Fc domain comprising a first subunit and a second subunit, wherein the Fc domain is a human IgG Fc domain.